{
    "clinical_study": {
        "@rank": "80881", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Nitric Oxide for Inhalation"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "oxygen"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this pilot study is to evaluate whether administration of nitric oxide\n      (NO)gas by oxygen hood at 20 ppm significantly increases PaO2, as compared to placebo gas\n      (oxygen), within one hour of initiation and with no significant adverse effects."
        }, 
        "brief_title": "Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation", 
        "completion_date": {
            "#text": "June 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "Lung Disease", 
            "Hypoxemia", 
            "Respiratory Acidosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acidosis", 
                "Acidosis, Respiratory", 
                "Lung Diseases", 
                "Anoxia"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is possible that administration of inhaled NO to neonates with abnormal gas exchange\n      earlier, rather than later as a rescue therapy in a moribund state, might accelerate the\n      transition of the circulation from the fetal to neonatal physiology and improve oxygenation.\n       This may in turn decrease the need for mechanical ventilation, its associated morbidity and\n      perhaps even ECMO.\n\n      This study is designed as a pilot study to evaluate the physiologic efficacy (rather than\n      effect on clinical outcomes) of NO administered by hood in improving oxygenation of neonates\n      with elevated A-a DO2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Gestational age >34 completed weeks (>=35)\n\n          -  Age <48 hours\n\n          -  A-a DO2 400 to 600, on two post-ductal arterial blood gases one hour apart, while on\n             100% O2 by oxygen hood\n\n          -  Post-ductal arterial access\n\n          -  Admitted to The University of Alabama Birmingham Regional NICU\n\n        Exclusion criteria:\n\n          -  Cardiac disease (structural disease with right to left or mixing lesions), not\n             including patent ductus arteriosus (PDA) or patent foramen ovale (PFO)\n\n          -  Rapid deterioration requiring mechanical ventilation before entry into the study\n\n          -  Major malformations\n\n          -  Major neurologic or metabolic disorder or other illness leading to hypoventilation\n             and hypercarbia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "120 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 10, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00041548", 
            "org_study_id": "CARLW1"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "given at 20 ppm for 1 hour then weaned off over 4 hours", 
                "intervention_name": "nitric oxide for inhalation", 
                "intervention_type": "Drug", 
                "other_name": "INOmax"
            }, 
            {
                "arm_group_label": "2", 
                "description": "given at 20 ppm for one hour, then weaned off over four hours", 
                "intervention_name": "Oxygen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nitric Oxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 9, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35233"
                }, 
                "name": "The University of Alabama Birmingham"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation", 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Waldemar Carlo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "PaO2 level", 
            "safety_issue": "No", 
            "time_frame": "at baseline, then every hour for 6 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041548"
        }, 
        "responsible_party": {
            "name_title": "Robert Small", 
            "organization": "INO Therapeutics"
        }, 
        "secondary_outcome": [
            {
                "measure": "Methemoglobin level", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline then every hour of treatment"
            }, 
            {
                "measure": "Alveolar-arterial oxygen gradient and ratio", 
                "safety_issue": "No", 
                "time_frame": "after 1 hour of treatment"
            }
        ], 
        "source": "INO Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "INO Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2010", 
        "why_stopped": "slow enrollment"
    }, 
    "geocoordinates": {
        "The University of Alabama Birmingham": "33.521 -86.802"
    }
}